The Wilms tumor suppressor gene (WT1) encodes an essential transcription factor regulating mammalian urogenital development. However, the function of WT1 in human endometrium is still unclear. The current study examined the involvement of WT1 in the regulation of IGF-binding protein-1 (IGFBP-1) and prolactin (PRL), which are specific markers of decidualization, in human endometrial stromal cells (ESCs) undergoing decidualization. ESCs isolated from proliferative-phase endometrium were incubated with cyclic adenosine monophosphate (cAMP) to induce decidualization. cAMP increased WT1 expression with the induction of IGFBP-1 and PRL. Knockdown of WT1 by small interfering RNA inhibited cAMP-induced expression of IGFBP-1 and PRL. cAMP also induced the recruitment of WT1 to the IGFBP-1 and PRL promoters. To investigate the mechanism by which WT1 is upregulated by cAMP, we focused on C/EBPb, a gene that regulates the expression of many genes during decidualization. Knockdown of C/EBPb decreased cAMP-increased WT1 expression. cAMP increased the recruitment of C/EBPb to the WT1 enhancer that is located approximately 14,000 bp downstream from the transcription start site. To test the endogenous function of the WT1 enhancer region on WT1 expression, the endogenous WT1 enhancer region was deleted by CRISPR/Cas9 system in HEK293 cells. The increase of WT1 expression by cAMP was not observed in the enhancerdeleted clones. Chromatin immunoprecipitation assay revealed that this enhancer region has high levels of H3K27ac and H3K4me1, which are active enhancer marks. These results show the role of WT1 in regulating decidualization in human ESCs. C/EBPb is an upstream gene that regulates WT1 expression by binding to the novel enhancer region. (Endocrinology 158: 3696-3707, 2017) 
H uman endometrial stromal cells (ESCs) undergo cyclic changes caused by steroid hormones during the menstrual cycle. One of these changes is decidualization, which is crucial for embryo implantation and maintenance of pregnancy (1, 2) . Impaired decidualization of endometrial stroma is associated with recurrent miscarriage, implantation failure, and unexplained infertility (3, 4) . A number of genes are upregulated or downregulated in ESCs undergoing decidualization (5, 6) .
Among these genes, IGF-binding protein-1 (IGFBP-1) and prolactin (PRL) are induced in ESCs during decidualization and are therefore recognized as markers of decidualization (1, 7, 8) . During decidualization, a number of transcription factors are activated and contribute to the dynamic changes of gene expressions in ESCs (9) (10) (11) (12) . The Wilms' tumor suppressor gene (WT1) encodes an essential transcription factor regulating mammalian urogenital development (13) . WT1 knockout mice show embryonic lethality and failure of kidney and gonad development (14) . Mutations in WT1 cause Wilms tumor, a form of pediatric kidney cancer (15, 16) , as well as a variety of human syndromes. Three of these disorders-WAGR (for "Wilms tumor, aniridia, genitourinary abnormalities, mental retardation"), Denys-Drash syndrome, and Frasier syndromeaffect the development of gonads and genitalia (17) (18) (19) . These syndromes also complicate malformations of the uterus, suggesting that WT1 has an important role in uterine development. Although most studies of WT1 have assessed its expression and roles in developing organs such as the kidneys and gonads, WT is also expressed in certain cell types, including uterine cells, throughout life (20) (21) (22) (23) (24) . Some transcription factors essential for organ development also have important physiological roles in adult organs. For example, steroidogenic factor 1 is a key transcription factor in the development and differentiation of steroidogenic tissues (25) . It also controls the expression of all the steroidogenic enzymes and cholesterol transporters required for steroidogenesis in adult steroidogenic tissue. Although WT1 has roles in adult organs, such as kidney and heart (23) , its role in the adult uterus is unclear. WT1 is expressed in human ESCs, and its expression level is increased upon decidualization (21, 22) , suggesting that WT1 has some key roles in decidualization. However, it is unknown whether WT1 is involved in the regulation of decidualization-related gene expression in human ESCs.
CCAAT/enhancer-binding protein b (C/EBPb) is a basic leucine zipper DNA-binding protein that acts as a regulator of uterine stromal cell proliferation and differentiation (12, 26) . Female mice lacking the C/EBPb gene are infertile due to implantation failure, and their uteri fail to undergo decidualization (26) . C/EBPb regulates the expression of many genes related to decidualization, including IGFBP-1 and PRL (9, 12) , although its effect on WT1 expression during decidualization is unclear.
In this study, we investigated the molecular mechanism by which WT1 regulates the expression of IGFBP-1 and PRL in ESCs undergoing decidualization. Here we report that WT1 is a downstream target gene of C/EBPb and regulates decidualization of human ESCs. We also identified a novel enhancer region of WT1, including a C/EBPb binding site, that was confirmed by using a genome editing technique.
Materials and Methods

Reagents
Dulbecco's modified Eagle medium (DMEM), L-glutamine, 13 trypsin-EDTA, streptomycin, and penicillin were purchased from Invitrogen (Carlsbad, CA 
ESC isolation
Human endometrial tissues were obtained at hysterectomy from patients with a normal menstrual cycle, aged 40-45 years, who underwent surgery for myoma uteri or early-stage cervical cancer. The patients were not on hormone therapy at the time of surgery. Informed consent was obtained from all participating patients, and ethical approval was obtained from the Institutional Review Board of Yamaguchi University Hospital. Endometrial samples used for ESC isolation were histologically diagnosed as being in the late proliferative phase according to published criteria (27) . Tissue samples were washed with Phenol Red-free DMEM containing 4 mM glutamine, 50 mg/mL streptomycin, and 50 IU/mL penicillin and minced into pieces of ,1 mm 3 . ESCs were isolated as reported previously (28) . In brief, tissues were minced, enzymatically digested with 0.2% collagenase in a shaking water bath for 2 hours at 37°C, and filtered through a 70-mm nylon mesh. Stromal cells in the filtrates were washed three times with the medium, and the number of viable cells was determined by Trypan blue dye exclusion. Under the microscope, all of the cells reacted with the stromal-reacting antibody vimentin (data not shown), indicating that they were homogeneous. The cells were also verified to be negative for the epithelial cell-reacting antibody cytokeratin (data not shown). Cells were seeded at 10 5 cells/cm 2 in 75-cm 2 tissue culture flasks and incubated in Phenol Red-free DMEM containing glutamine, antibiotics, and 10% dextrancoated charcoal-stripped FBS at 37°C, 95% air, and 5% CO 2 . At confluence, cells were treated with 13 trypsin-EDTA and subcultured into 25-cm 2 tissue culture flasks. At 80% confluence after the first passage, the cell culture medium was changed to the treatment medium.
Cell culture
Normal human dermal fibroblasts (HDFs) (Cell No. RCB0222) were obtained from the Riken Cell Bank (Tsukuba, Japan). Cells were seeded in 75-cm 2 tissue culture flasks and incubated in Phenol Red-free DMEM containing glutamine, antibiotics, and 10% dextran-coated charcoal-stripped FBS at 37°C, 95% air, and 5% CO 2 . At confluence, cells were treated with 13 trypsin-EDTA and transferred into eight-chamber BD Falcon glass culture slides (BD Biosciences Discovery Labware, Bedford, MA). HEK293 cells were seeded in 75-cm 2 tissue culture flasks and incubated in Phenol Red-free DMEM containing glutamine, antibiotics, and 10% dextran-coated charcoal-stripped FBS at 37°C, 95% air, and 5% CO 2 . At confluence, cells were treated with 13 trypsin-EDTA and subcultured into 6-well plates and used for the genome editing experiment as described below.
To induce decidualization, ESCs were incubated with test medium (Phenol Red-free DMEM supplemented with glutamine, antibiotics, and 2% dextran-coated charcoal-stripped FBS) with or without db-cAMP (0.5 mM) for 4 days at 37°C in an atmosphere of 95% air and 5% CO 2 . The cells were then used for the experiments described below. cAMP is considered as a second messenger of progesterone for decidualization because progesterone increases intracellular cAMP concentrations in ESCs (29) . The concentration of db-cAMP and the period of incubation used in this study were based on our previous report, in which the IGFBP-1 messenger RNA (mRNA) level reached a peak 4 days after cAMP stimulation and maintained high levels thereafter (29) . cAMP treatment for ,4 days was not enough to induce decidualization (30) . Therefore, we evaluated decidualization on day 4 after cAMP stimulation. The medium was changed every other day. Cells isolated from one patient were incubated one time in triplicate. Cells from three individuals were incubated in a single experiment.
Immunohistochemistry
Tissue samples from the late proliferative phase and from the late secretory phase and decidua of early pregnancy were immunostained as reported previously (29) . The endometrial tissues were fixed in formalin, embedded in paraffin, and sectioned (5 mm thick). The tissue sections were deparaffinized in xylene and dehydrated in a graded series of ethanol. The sections were stained with Histofine simple stain MAX-PO(R) (Nichirei Co. Ltd., Tokyo, Japan) using a rabbit polyclonal antibody to WT1 [Research Resource Identifier (RRID):AB_2043201; Abcam, Cambridge, UK]. Peroxidase activity was visualized by incubating the sections with 3,3 0 -diaminobenzidine-4 HCl (Nakalai Tesque Co. Ltd., Tokyo, Japan) in 0.05 M Tris-HCl buffer (pH 7.6) containing 0.01% H 2 O 2 for 3 minutes. Control sections were incubated with normal rabbit serum. The sections were counterstained with Meyer's hematoxylin. The cells were immunocytochemically stained as reported previously (31) . ESCs and HDFs were cultured on eight-chamber BD Falcon glass culture slides, washed with phosphate-buffered saline (PBS), fixed with 4% paraformaldehyde, blocked and permeabilized for 1 hour at 37°C with 2% bovine serum albumin with 0.1% Triton X-100, incubated with rabbit polyclonal antibody to WT1 (Abcam plc) overnight at 4°C using normal rabbit IgG (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) as a negative control, washed with PBS, incubated for 1 h at room temperature with the goat anti-rabbit antibody AlexaFluor 488 (Life Technologies, Carlsbad, CA), incubated with 4,6-diamidino-2-phenylindole to label the nuclei, and observed with a laser-scanning microscope (LSM 780; Carl Zeiss, Oberkochen, Germany).
Real-time reverse transcription polymerase chain reaction
Total RNA was isolated from the cultured cells with an RNeasy Mini Kit (Qiagen, Valencia, CA). The RNA was reverse transcribed as reported previously (32) . For polymerase chain reaction (PCR) amplification, first-strand cDNA was synthesized from 1 mg total RNA with reverse transcription (Invitrogen) in 20 mL of reaction mixture. Amplicons of WT1, IGFBP-1, PRL, C/EBPb, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were amplified by real-time reverse transcription PCR (RT-PCR) as reported previously (33) with sequence-specific primer sets (Supplemental Table 1 ).
Western blotting
Whole cell lysates were prepared using loading buffer reagents (Santa Cruz Biotechnology) without trypsin treatment. Equal amounts of total protein were electrophoresed on a 10% sodium dodecyl sulfate polyacrylamide gel. The proteins were transferred to polyvinylidene difluoride membranes (ATTO, Tokyo, Japan). The membranes were blocked with blocking solution [5% skimmed milk with 0.1% Tween-20 dissolved in Tris-buffered saline (pH 7.5)]; incubated with the first antibody for WT1 (RRID:AB_2043201; Abcam plc), C/EBPb (RRID: AB_2260363; Santa Cruz Biotechnology), and b-tubulin (RRID: AB_477577; Sigma), which were diluted in blocking solution; incubated with the peroxidase-conjugated second antibody diluted in blocking solution; visualized with the ECL-Western blotting detection system (Amersham, Aylesburg, UK) according to the manufacturer's protocol; and used to expose hyperfilm-ECL (Amersham). To reuse the blot, the membranes were stripped in Restore Western stripping buffer (Pierce, Rockford, IL).
Lipid-mediated transfection of small interfering RNA duplexes WT1 ON-TARGET plus SMART pool, C/EBPb ON-TARGET plus SMART pool, and ON-TARGET plus Non-Targeting pool small interfering RNA (siRNA) were purchased from Dharmacon (Lafayette, CO). ESCs were plated in medium lacking antibiotics at approximately 5 3 10 4 cells in 6-well plates. At 50% confluence, siRNA duplexes (20 nM) and RNAi MAX (2.5 mL/well) (Invitrogen) diluted in Optimem (Invitrogen) were transfected to ESCs. The medium was changed 4 hours later. After 48 hours of transfection, cells were incubated in the presence or absence of cAMP for 4 days.
Chromatin immunoprecipitation assay
The levels of transcription factor recruitment and histone modification status were examined by chromatin immunoprecipitation (ChIP) assay according to the protocol for the ChIP assay kit (Upstate Biotechnology, Lake Placid, NY) as reported previously (9, 34) with some modifications. Cells were cross-linked by the addition of formaldehyde into the medium at a final concentration of 1% and incubated for 10 minutes at 37°C. Cross-linking was terminated by the addition of glycine (0.125 M, final concentration). Cells were washed with ice-cold PBS containing protease inhibitors (Sigma) and resuspended in ChIP lysis buffer [1% SDS, 10 mM EDTA, 50 mM Tris-HCl (pH 8.0) with protease inhibitors]. The lysates were sonicated using a Bioruptor ultrasonicator (Cosmo-bio, Tokyo, Japan), precleared with salmon sperm DNA-protein A at 4°C for 4 hours, and diluted with ChIP dilution buffer [0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl (pH 8.0), 167 mM NaCl, with protease inhibitors]. Five percent of the supernatants were kept as input controls (INPUT). Dynabeads Protein A (Invitrogen) was incubated with antibodies for WT1 (RRID:AB_632611; Santa Cruz Biotechnology), C/EBPb (RRID:AB_2260363; Santa Cruz Biotechnology), H3K27ac and H3K4me1 (a generous gift from Dr. Kimura) (35), and normal mouse or rabbit IgG (Invitrogen) at 4°C overnight. The precleared chromatin was incubated with antibody-bound Dynabeads for 6 hours at 4°C. Immune complexes were collected and washed once for 5 minutes on a rotating platform with 1 mL each of the following buffers in sequence: low-salt wash buffer [0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl (pH 8.0), 150 mM NaCl], high-salt wash buffer [0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl (pH 8.0), 1500 mM NaCl], LiCl wash buffer [250 mM LiCl, 1% Nonidet P-40, 1% sodium deoxycholate, 1 mM EDTA, 10 mM Tris-HCl (pH 8.0)], and twice with TE [10 mM Tris-HCl (pH 8.0), 1 mM EDTA]. Immune complexes were eluted with 200 mL elution buffer (1% SDS, 0.1 M NaHCO 3 , 10 mM DTT). The immunoprecipitated (IP) chromatin complexes and INPUT were incubated at 65°C overnight to reverse the cross-linking and subjected to proteinase K treatment. Purified DNA using a QIAquick PCR purification kit (QIAGEN) served as the template for PCR using various primer sets (Supplemental Table 1 ) to amplify specific regions. The GAPDH enhancer region was used as a control region to show that all samples had the same modification levels in the GAPDH enhancer region. Real-time PCR was used to determine the relative levels of WT1 and C/EBPb recruitment and the histone modification status of each target sequence. The ratio of IP DNA to the INPUT DNA sample (%INPUT) was calculated as reported previously (36) .
Deletion of the WT1 enhancer region by CRISPR/Cas9 system pCAGmCherry-gRNA (Addgene plasmid # 87110) was a gift from Dr. Juan Carlos Izpisua Belmonte (The Salk Institute). pCas9_GFP was a gift from Kiran Musunuru (Addgene plasmid #44719). To construct single guide RNA (sgRNA) expression vectors, each 20-bp target sequence was subcloned into pCAGmCherry-gRNA Vector. The CRISPR/Cas9 target sequences used in this study are sgRNA1; TGAGGTGGTGG-CACCTACAGTGG and sgRNA2; and TACTGGGCCGAAG-CATGCTCAGG, in which the 3 bp PAM sequences are underlined. HEK293 cells were plated in medium lacking antibiotics at approximately 3 3 10 5 cells in 6-well plate 1 day before transfection. At 50% confluence, Cas9 plasmid (1 mg) and two gRNA plasmids (0.5 mg each) were transfected to HEK293 cells with Lipofectamine 3000 (Invitrogen). After 48 hours of transfection, cells were trypsinized, diluted, and plated in 6-well plates. After 10 days, individual colonies were isolated, harvested, seeded in 24-well plates, grown until confluence, and transferred to 6-well plates. To screen the enhancer deletion, the genomic DNA of each clone was analyzed by PCR amplification with primers flanking the two sgRNAs. Genomic DNA (20 ng) was used and amplified with PrimeSTAR GXL DNA Polymerase (TaKaRa, Ohtsu, Japan). The resulting products were subjected to agarose gel electrophoresis and purified using a QIAquick gel extraction kit (QIAGEN). The PCR products were cloned into pGEM-T easy vector (Promega, Tokyo, Japan), and sequencing was performed using an ABI automated sequencer with BigDye terminators (Applied Biosystems, Foster City, CA). Two wild-type clones (Wt1 and Wt2) and two enhancer-deleted clones (Mut1 and Mut2) were used as representative clones. These cells were incubated with test medium (Phenol Red-free DMEM supplemented with glutamine, antibiotics, and 10% stripped FBS) with or without db-cAMP (0.5 mM) for 4 days at 37°C in an atmosphere of 95% air and 5% CO 2 . WT1 mRNA expression was analyzed by real-time RT-PCR.
Statistical analysis
Statistical significance was determined by one-way analysis of variance. After analysis of variance, the Tukey-Kramer test was applied to analyze differences between groups. An unpaired t test was applied to analyze the difference between two groups. All statistical analyses were performed using SPSS for Windows version 11 (SPSS Inc., Chicago, IL). Differences were considered significant at P , 0.05.
Results
WT1 expression in human ESCs and the effect of cAMP on WT1 expression
The expression of WT1 in ESCs was examined by immunocytochemical staining (Fig. 1A) . HDFs were used as negative control cells that do not express WT1. WT1 was expressed in ESCs and localized in the nucleus. As expected, WT1 expression was not observed in HDFs. These observations were confirmed by real-time RT-PCR (Fig. 1B, left panel) and Western blotting (Fig. 1B, right  panel) . cAMP increased the mRNA and protein expression levels of WT1 with the induction of IGFBP-1 and PRL mRNA in ESCs (Fig. 1B and 1C) . Immunohistochemistry also revealed that WT1 was expressed in stromal cells obtained from the proliferative-phase endometrium (Fig. 1D) . Stronger expression of WT1 was observed in the stromal cells that were morphologically identified as predecidual cells in the late secretory phase endometrium and decidual cells of early pregnancy.
Involvement of WT1 in cAMP-induced gene expression of IGFBP-1 and PRL
To examine whether the stimulatory effects of cAMP on mRNA expression of IGFBP-1 and PRL are mediated through WT1, ESCs were transfected with WT1 siRNA. Basal (control) and cAMP-increased WT1 mRNA and protein expression were suppressed by siRNA treatment (Fig. 2A) . cAMP-induced IGFBP-1 and PRL mRNA expression was significantly inhibited by WT1 siRNA (Fig. 2B) . The morphological changes induced by decidualization stimulus with cAMP were not altered by WT1 knockdown (data not shown).
cAMP-induced WT1 recruitment to the promoter regions of IGFBP-1 and PRL The 5 0 -upstream region between 280 and 2270 bp of the IGFBP-1 gene is critical for the regulation of IGFBP-1 expression because many cis-regulatory elements are located within this region, such as progesterone receptor response element and insulin response sequence, including a FOXO1 binding site (Fig. 3A) (37-39) . We previously reported that C/EBPb, one of the important transcription factors for decidualization, indirectly binds to the IGFBP-1 promoter region by cAMP stimulation in ESCs (9) . The PRL promoter region between 2285 and 2310 bp contains the cis-regulatory element for C/EBPb, which mediates cAMP-induced PRL gene expression (Fig. 3A ) (9, 10, 40) . However, it is unclear whether WT1 is recruited to these promoter regions by decidualization stimulus. It is reported that WT1 binds to the 9-bp DNA sequence GCG(G/T)GGGCG, which is similar to the consensus binding sequence recognized by EGR-1 (41, 42) . A search of the IGFBP-1 and PRL promoter regions by JASPAR (http://jaspar.binf.ku.dk/) showed that they both contain a WT1 consensus binding sequence (Fig. 3A) . Therefore, ChIP primers were designed to cover these regions (IGFBP-1 promoter primer, 249 to 2212 bp; PRL promoter primer, 2124 to 2363 bp). cAMP significantly increased the WT1 binding in the promoter regions of IGFBP-1 and PRL (Fig. 3B) . These results showed that WT1 upregulates IGFBP-1 and PRL expression by binding to the promoter regions during decidualization.
Involvement of C/EBPb in the cAMP-increased gene expression of WT1
Because we revealed that upregulation of WT1 by cAMP is important for decidualization, the detailed mechanism by which cAMP increases the expression of WT1 in ESCs was also examined. For this purpose, we focused on C/EBPb because it is an important transcription factor for decidualization by regulating the expression of many genes (9, 12) . In addition, it is reported that C/EBPb regulates WT1 expression during heart development in embryonic mice (43) . Therefore, we hypothesized that C/EBPb is involved in the cAMP-increased gene expression of WT1 during decidualization in human ESCs. To examine whether the stimulatory effects of cAMP on mRNA expression of IGFBP-1 and PRL are mediated through C/EBPb, ESCs were transfected with C/EBPb siRNA. Basal (control) and cAMP-increased C/EBPb mRNA and protein expression was clearly suppressed by siRNA treatment (Fig. 4A) . The expression of cAMP-induced IGFBP-1 and PRL mRNA was significantly inhibited by C/EBPb siRNA (Fig. 4B) , as we reported previously (9) . C/EBPb knockdown also decreased cAMP-increased WT1 mRNA expression but did not affect the basal (control) level of WT1. Furthermore, we examined the detailed mechanism by which WT1 is upregulated by cAMP through C/EBPb. For this purpose, we investigated the promoter and enhancer region of WT1 to see whether potential C/EBPb binding sites exist within these regions. We checked ChIP sequence data of genome-wide C/EBPb binding in other cell lines that are provided from the Encyclopedia of DNA Elements (ENCODE) project (44) . K562 cells are a human immortalized myelogenous leukemia line that highly expresses WT1 (45) . Therefore, C/EBPb binding peaks around the WT1 gene in K562 cells was searched. A C/EBPb binding peak was observed in the third intron of WT1 gene in K562 cells, which is located approximately 14,000 bp downstream from the transcription start site, and a JASPAR search found a C/EBPb consensus binding sequence in this region. We thus hypothesized that the region around the C/EBPb binding site serves as an intronic enhancer region of WT1 that is involved in cAMP-increased WT1 expression in ESCs undergoing decidualization. Using ChIP assay, we examined whether C/EBPb is recruited to this C/EBPb binding site in response to a stimulus by cAMP. ChIP primers were designed surrounding the C/EBPb consensus binding sequence (WT1 enhancer primer, +14,218 to +14,390 bp) (Fig. 5A) . cAMP significantly increased C/EBPb recruitment to the enhancer region of WT1 (Fig. 5B) , supporting the above hypothesis.
Effect of WT1 enhancer deletion on cAMP-increased WT1 mRNA expression
To test the endogenous function of the WT1 enhancer region on WT1 expression, we sought to delete this enhancer sequence from endogenous locus. We explored CRISPR/Cas9 technology to generate the cell lines that lacks WT1 enhancer region. In the CRISPR/Cas9 system, an sgRNA targets the Cas9 protein to a specific genomic location and generates a double-strand break. Random mutations can be generated when the DNA break is repaired via nonhomologous end joining (46, 47) . By introducing two sgRNAs flanking the C/EBPb binding site in the WT1 enhancer region into a cell, two DNA breaks may be generated simultaneously on the same chromosome, leading to the deletion of the WT1 enhancer region, including the C/EBPb binding site. Due to the low efficiency of transfection and the difficulty of single cell culture for cloning, we could not generate proper ESC lines (data not shown). HEK293 cells also express WT1 (48) and are widely used for experiments on genome editing (49) . Therefore, we used HEK293 cells to examine the WT1 enhancer function by the genome editing approach. sgRNAs were designed flanking the C/EBPb binding site in the WT1 enhancer region (Fig. 6A) . HEK293 cells were cotransfected with CRISPR/Cas9 and two sgRNA constructs. After cell cloning, the genomic DNAs of each clone were analyzed by PCR amplification with primers flanking two sgRNAs (Fig. 6A) . By the successful deletion of the 133-bp region and repair of DNA through nonhomologous end joining, a 222-bp product was expected, whereas a 355-bp product should be observed from genomic DNA in wild-type clones. We obtained several clones that had the desired enhancer deletion. Figure 6B shows the result of PCR amplification from genomic DNAs of four representative clones. A 355-bp PCR product was observed in clones 1 and 2, indicating that they were wild-type clones (Wt1 and Wt2). In clones 3 and 4, a smaller PCR product of 222 bp was observed without the larger 355-bp product. Therefore, they were considered as enhancerdeleted clones in both alleles (Mut1 and Mut2). These clones were used as representatives of wild-type clones (Wt1 and Wt2) and enhancer-deleted clones (Mut1 and Mut2). DNA sequencing was also performed to confirm the deletion of the desired region in the Mut1 and Mut2 clones (Fig. 6C) . Both clones had the same deletion on both alleles. To examine whether the deletion of the enhancer region abolishes the ability to respond to cAMP and to increase WT1 mRNA expression, each clone was treated with or without cAMP. cAMP significantly increased the mRNA expression level of WT1 in Wt1 and Wt2 clones. This increase was not observed in the Mut1 and Mut2 clones. These results indicate that the WT1 enhancer region, including the C/EBPb binding site, is responsible for cAMP-increased WT1 expression.
Epigenetic characterization of the enhancer region of WT1
The WT1 expression seen in in ESCs but not in HDFs could be due to the histone modifications in the chromatin structure in the C/EBPb binding region of the WT1 enhancer region. To test this idea, we examined he status of H3K27ac and H3K4me1, which are enhancer marks (50, 51) , by ChIP assay. The levels of H3K27ac and H3K4me1 in the WT1 enhancer region were significantly higher in ESCs than in HDFs (Fig. 7, left panel) , suggesting that the chromatin structure of the WT1 enhancer region in ESCs is an activated structure and contributes to WT1 expression. The H3K27ac and H3K4me1 levels remained high after cAMP stimulation in ESCs. The GAPDH enhancer region did not show any differences of H3K27ac and H3K4me1 levels between the three cells (Fig. 7, right panel) , suggesting that the differences of histone modification levels in the WT1 enhancer region were not due to differences in technical quality between the samples. These results indicate that the C/EBPb binding region in the WT1 enhancer region possesses an enhancer signature that is epigenetically activated and contributes to WT1 expression in ESCs. We previously reported that only 23% of upregulated genes by decidualization stimuli were accompanied by an increase of H3K27ac (5) . Therefore, it is not surprising that the WT1 enhancer region did not show an increase of H3K27ac or H3K4me1 levels by cAMP. We speculate that active histone marks are fully induced in the WT1 enhancer region even in nondecidualized ESCs and contribute to keeping the chromatin structure relatively loose. Therefore, cAMP did not further increase the H3K27ac level. This enables C/EBPb activated by a decidualization stimulus to easily access the binding region and thereby enhances gene expression.
Discussion
WT1 is an essential transcription factor regulating mammalian urogenital development (13) . It is expressed in mesoderm-derived adult tissues, including the uterus (23, 24) . We examined WT1 involvement in the human endometrium, in which it regulates the gene expression of IGFBP-1 and PRL in human ESCs undergoing decidualization.
The 5 0 -upstream regions of the IGFBP-1 and PRL genes are critical for their regulation because they contain many cis-regulatory elements (Fig. 3A) (9, (37) (38) (39) (40) . WT1 binds to the same consensus binding sequence that EGR-1 binds to (41, 42) . The IGFBP-1 and PRL promoter regions have this consensus sequence, and cAMP recruits WT1 to it (Fig. 3B ). To date, there have been no reports demonstrating WT1 recruitment to the IGFBP-1 and PRL promoter regions in any other type of cells. Therefore, our study shows an important function of WT1 in regulating IGFBP-1 and PRL expression by the direct binding to their promoter regions during decidualization.
C/EBPb is a crucial transcription factor for decidualization, regulating the expression of about 1300 genes related to decidualization in human ESC (12) . We previously reported that C/EBPb upregulates IGFBP-1 and PRL expression by binding to their promoter regions (9) . The current study clearly showed that WT1 is one of the decidualization-related genes regulated by C/EBPb (Fig. 4) . So far, involvement of C/EBPb in WT1 expression has been observed only during heart development in embryonic mice (43) . In addition, using ChIP assay, we identified a C/EBPb binding region in the third intron of WT1 gene that is located approximately 14,000 bp downstream from the transcription start site. Recently, not only the regions near the transcription start site but also the distal enhancer regions that are far from TSS have been considered as important cis-elements for transcription. Because long-range chromatin interactions, such as enhancerpromoter interactions, can regulate gene expression levels (52, 53) , our finding suggests that an interaction between the promoter regions and C/EBPb binding enhancer region is involved in the upregulation of WT1 expression during decidualization in human ESCs. Although the third intron has another potential C/EBPb binding region (43), we did not observe an increase of C/EBPb recruitment in this region by cAMP stimulation in ESCs (data not shown). It is therefore likely that the C/EBPb binding region we identified is more closely associated with the regulation of WT1 expression during decidualization than other potential C/EBPb binding regions.
To test the in vivo function of the enhancer region on WT1 expression, we explored CRISPR/Cas9 technology to generate the cell lines that lack the WT1 enhancer region. Until recently, validating the in vivo function of a putative enhancer has proven technically difficult. Reporter assays confirm that the sequence can function as an enhancer exogenously, but it does not demonstrate whether a distal target gene can be activated by the enhancer in vivo. The CRISPR/Cas9 system has proven to be a highly efficient genome editing tool and offers a promising method to validate enhancer functions in vivo (54, 55) . By generating the cell lines that lack the WT1 enhancer region, we clearly showed that this region is responsible for cAMP-increased WT1 expression. Because we used HEK293 cells, we cannot neglect the possibility that regulation of WT1 by C/EBPb in ESCs is different from that in HEK293 cells. However, it is difficult to generate mutated ESC clones because ESCs are primary cultured cells, which have low efficiency of transfection and which are difficult to use for single-cell culture for cloning. Taken together, our results directly show that the C/EBPb binding region that we identified is a novel enhancer region involved in the regulation of WT1 expression.
In summary, our results show that WT1 has a role in the human endometrium, in which it is one of transcription factors that regulate IGFBP-1 and PRL expression in human ESCs. Interestingly, C/EBPb, another important transcription factor for decidualization, is an upstream gene that regulates WT1 expression by binding to the novel enhancer region. We also used CRISPR/Cas9 technology to generate cell lines that lack the WT1 enhancer region and confirmed that transcriptional activity in this region enhances WT1 expression. Our work reveals a molecular mechanism in which the C/EBPb-WT1 pathway plays an important role in decidualization in human ESCs. Correspondence and Reprint Requests: Norihiro Sugino, MD, PhD, Department of Obstetrics and Gynecology, Yamaguchi University Graduate School of Medicine, Minamikogushi 1-1-1, Ube 755-8505, Japan. E-mail: sugino@yamaguchi-u. ac.jp.
Disclosure Summary: The authors have nothing to disclose.
